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Abstract
Background: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) has emerged as an urgent
global health threat and is by the World Health Organization ranked as priority 1 among pathogens in need of new
treatment. Studies have shown high mortality in Tanzanian children with ESBL-E infections. Gut colonization of
ESBL-E, which is a potential risk factor of ESBL-E infections, is reported to be very high among children in Tanzania.
Probiotics may potentially reduce gut colonization of multidrug-resistant bacteria. However, there is limited data on
whether probiotics may reduce ESBL-E carriage in infants. The ProRIDE Trial aims to evaluate whether the use of
probiotics can reduce morbidity and mortality among infants in Haydom, Tanzania, and whether this effect is
associated with a reduction in ESBL-E colonization and/or infections.
Methods/design: This large randomized double-blinded placebo-controlled trial aims to recruit 2000 newborn
infants at Haydom Lutheran Hospital and the surrounding area in the period of November 2020 to November
2021. Participants will be enrolled from days 0 to 3 after birth and randomized to receive probiotics or
placebo for 4 weeks. Participants will be followed-up for 6 months, during which three visits will be made to
collect clinical and demographic information, as well as rectal swabs and fecal samples which will be
subjected to laboratory analysis. The primary composite outcome is the prevalence of death and/or
hospitalization at 6 months of age.
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Discussion: As the use of probiotics may give a more favorable gut composition, and thereby improve
health and reduce morbidity and mortality, the results may have implications for future therapy guidelines in
Africa and internationally.
Trial registration: ClinicalTrials.gov NCT04172012. Registered on November 21, 2019
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Introduction
Background and rationale {6a}
Infections continue to be a considerable cause of death
and disease among infants in low- and middle-income
countries. In sub-Saharan Africa, infections contribute
to three–forth of under-five mortality [1]. In Tanzania,
the under-five mortality was reported at 55 per 1000 live
births in 2016, whereof 42 deaths occurred before the
age of one year [2]. An increasing prevalence of anti-
microbial resistance (AMR) is among the most urgent
global threats [3]. Previous studies of hospitalized chil-
dren in Tanzania have shown that blood-stream infec-
tions (BSIs) caused by extended-spectrum beta-
lactamase-producing Enterobacteriaceae (ESBL-E)
caused a mortality rate of more than 70%, compared to
20% or less for malaria infections and BSI with suscep-
tible bacteria [4, 5]. A potential risk factor of ESBL-E in-
fection is gut colonization with ESBL-E [6–8].
Colonization rates have now evolved towards a global
pandemic with developing countries being affected most
[9]. Our research group has previously shown that
around two–third of Tanzanian infants below three
months of age had fecal carriage of ESBL-E [10].
Probiotics are live microorganisms that, when admin-
istered in adequate amounts, confer a benefit to the host.
Probiotics are currently widely used in newborns and
children [11]. They have proven beneficial effects in pre-
term infants reducing necrotizing enterocolitis and sep-
sis [12, 13], and this has been observed both in high-,
middle-, and low-income countries [14]. In term infants,
a study from India was conducted where more than
4500 term-born infants were randomized to receive ei-
ther the probiotic bacteria Lactobacillus plantarum
along with fructo-oligosaccharide, a plant-derived pre-
biotic (the combination of probiotic and prebiotic is
coined “synbiotic”) or placebo [15]. This simple inter-
vention reduced the composite outcome of severe infec-
tions and/or death by 40%, from 9.0% in the placebo
group to 5.4% in the synbiotic group.
A stable and resilient commensal gut microbiota is es-
sential for “colonization resistance”; the ability to pre-
vent intestinal colonization and invasion by pathogens.
Resurrecting the gut microbiota by the use of probiotics
has been put forward as a new strategy in combatting
intestinal carriage of AMR-bacteria [16]. To what extent
probiotics can reduce the spread of AMR is still under
investigation [17], but probiotic bacteria produce bacte-
riocins that improve mucosal integrity and thereby may
reduce the pathogenic bacterial population and promote
“colonization resistance” [16]. There is limited data on
which probiotic strains that most effectively may reduce
AMR in children. In adults and older children, lactobacilli
are often used for conditions like antibiotic-associated
diarrhea and gastroenteritis [18, 19]. In breastfed infants,
bifidobacteria constitute more than 80% of the gut micro-
biota, and when given in combination with human milk, it
has decreased the share of Enterobacteriales in the feces of
infants [20]. Breastfeeding, which promotes bifidobacterial
dominance, appears to protect infants from colonization
with AMR bacteria [21, 22]. Probiotic bifidobacterial
strains were also shown to inhibit the transfer of beta-
lactam resistance among Enterobacteriaceae in gnoto-
biotic mice [23] and reduce AMR gene carriage in a ran-
domized trial of 60 term infants [24]. In our own studies
among extremely preterm infants supplemented with a
probiotic product containing bifidobacteria and lactoba-
cilli, we found no ESBL-E in stool samples despite massive
exposure to antibiotic therapy. In contrast, ESBL-E was
detected in the stool of moderate preterm infants and full-
term infants not given probiotics and with less or no
antibiotic exposure [25]. This indicates that a probiotic
combination may prevent AMR development, but larger
studies are needed to confirm these promising results.
Except from the study by Panigrahi et al. [15], no other
large randomized clinical trials (RCT) have investigated
whether bifidobacterial probiotic supplementation can
reduce mortality and infection-related morbidity in in-
fants in low-income countries. More specifically, no
large RCTs have investigated whether probiotics may re-
duce ESBL-E colonization in infants.
We plan to conduct a large RCT among term infants
in North-East Tanzania to evaluate whether the use of
probiotics can reduce infection-related morbidity and
mortality, similar to the Panigrahi trial [15]. Secondly,
we will investigate whether potentially beneficial effects
are associated with a reduction in ESBL-E colonization
and/or infections.
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Objectives {7}
The research question is Among term-born healthy in-
fants in Tanzania (P-population), will treatment with
probiotics (I-intervention) compared to placebo (C-com-
parison) lead to a 40% reduction in hospitalizations and
death, and in reduced fecal colonization of ESBL-E (O-
outcome)?
Overall objective of the study
The present randomized placebo-controlled clinical trial
will evaluate whether administration of probiotics for
the first 4 weeks of life, compared to placebo, can reduce
morbidity and mortality by preventing ESBL-E carriage
and/or infections among infants in Haydom and sur-
rounding area, Tanzania at follow-up 6 weeks and 6
months after birth.
Specific objectives of the study
1. To assess and compare mortality among groups
receiving probiotics or placebo.
2. To determine and compare episodes of infections
(i.e., sepsis, diarrhea) leading to hospitalization
among groups receiving probiotics or placebo.
3. To determine and compare the prevalence of ESBL-E
colonization among groups receiving probiotics or
placebo.
4. To determine and compare the bacterial causes of
sepsis, including antimicrobial susceptibility
patterns, among groups receiving probiotics or
placebo.
5. To assess and compare the effect of probiotics on
growth among groups receiving probiotics or
placebo.
6. To determine and compare the gut microbiota
composition and diversity among groups receiving
probiotics or placebo.
7. To determine and compare the gut metabolome
composition among groups receiving probiotics or
placebo.
8. To determine and compare the gut inflammatory
markers among groups receiving probiotics or
placebo.
9. To determine the bacterial causes of sepsis,
including antimicrobial susceptibility patterns for all
children under 1 year of age admitted with fever
during the study period.
Trial design {8}
The ProRIDE Trial is a double-blinded, placebo-
controlled RCT with two arms. More specifically, it is a
parallel group, superiority study with 1:1 allocation of
the randomized product (active probiotics or placebo).
Methods: participants, interventions, and
outcomes
Study setting {9}
Patients will be recruited among newborns; born at
Haydom Lutheran Hospital (HLH) in North East
Tanzania and out-born newborns in the surrounding
area. HLH is located in the Mbulu district, at the western
end of the Manyara Region in the North-Central
Tanzania, about 300 km south-west from regional center
Arusha. The HLH catchment area consists of four admin-
istrative divisions, three districts, and two regions. These
are the Dongobesh and Haydom divisions in Mbulu
District, the Basotu Division in Hanang District (Manyara
Region), and the Nduguti Division in Iramba District
(Singida Region). The hospital serves a population of
more than two million people from five regions. An-
nually, there are more than around 3900 deliveries in
the hospital, and in 2018, the neonatal mortality rate
in Tanzania was around 21/1000 live births [26].
Eligibility criteria {10}
Inclusion criteria
Healthy newborn infants with a birth weight (BW) equal
or above 2.0 kg are eligible for inclusion. Newborn in-
fants have to come from families who are long-term or
permanent residents in the defined catchment area for
this trial (30 km radius from HLH) in Tanzania. Parents
have to be able and willing to complete study visit (in-
cluding required study procedures) schedules over the 6
months proposed follow-up. This also includes that they,
if possible, bring their child to the hospital in case of any
intercurrent illness. Parents have to sign an informed
consent form (ICF) and have to agree that the child can-
not participate in another clinical trial during the study
period.
Exclusion criteria
BW below 2.0 kg, refusal of informed consent and/or
other health problems/illness including obvious congeni-
tal malformations.
Who will take informed consent? {26a}
Pregnant women in their last trimester, visited at home
or attending the last antenatal care visit at HLH, will re-
ceive oral and written information about all aspects of
the study before giving consent to let their future child
participate in the study. Trained research assistants who
speak the local language will be in charge of obtaining
informed consent before recruitment.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
On the consent form, participants will be informed
about the collection of stool samples and clinical data
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and that participating in the study is completely volun-
tary and that parents have the right to withdraw the in-
clusion of their child at any time.
Interventions
Explanation for the choice of comparators {6b}
Currently, there is no standard therapy for preventing
ESBL-E colonization in term infants and thus, “the-best-
available therapy” is no therapy. Therefore, the compara-
tor group will receive an inactive placebo agent.
Intervention description {11a}
The active group will receive the investigational product
(IP); a commercially available multi-strain probiotic
product (LaBiNIC® probiotic drops, Biofloratech Ltd.,
Surrey, UK). The product is already widely used in the
UK (at hospitals in the National Health Service) and in
other European countries [27, 28]. Previous studies in
developing countries have used from 7 days (India [15])
to 60 days (Botswana [29]) intervention with probiotic
supplementation in infants.
Five drops (0.2 ml) of the IP contain two billion (total)
of Lactobacillus acidophilus NCFM, Bifidobacterium bifi-
dum Bb-06, and Bifidobacterium infantis Bi-26 probiotics
(equal amount of all three strains), suspended in
pharmaceutical-grade capric MCT (medium-chain trigly-
ceride) oil and Aerosil® 200 Pharma (inactive ingredients).
Each bottle contains 5–5.5 ml and will be administered or-
ally once daily for 4 weeks to “bottle empty” (five drops
per day). The placebo group will receive placebo drops
containing only the inactive ingredients; a capric MCT-oil
and AEROSIL® 200 Pharma. AEROSIL® 200 Pharma is an
additive for food and pharmaceutical products with a
high-quality standard and with production processes
based on the quality concepts such as ISO 9001, HACCP,
FAMI-QS, and IPEC-GMP. The MCT-oil and AEROSIL®
200 Pharma are also constituents of the active IP. The pla-
cebo is produced by the same company that manufactures
the IP (Biofloratech Ltd., Surrey, UK). The MCT-oil is
used as a vehicle for the probiotic bacteria in the IP, and
the taste and color are identical, and it will be produced
and dispensed in identical bottles to the IP.
Criteria for discontinuing or modifying allocated
interventions {11b}
Study participants will be discontinued from participa-
tion in the study if any clinical adverse event (AE), la-
boratory abnormality, or other medical condition or
situation occurs during the 4-week intervention. Study
participants will also be discontinued from participation
in a situation where continued participation is not in the
best interest of the participants. Participants are free to
withdraw from participating in the study at any time
upon request. In any case, participants will be given
appropriate care under medical supervision until the
symptoms of any AE resolve or the participant’s condi-
tion becomes stable.
Strategies to improve adherence to interventions {11c}
During recruitment, allocation and the first follow-up
mothers/caretakers will receive information on how to
administer the drops appropriately and the importance
of completing the course. Adherence will also be evalu-
ated during the first and second follow-up visits by ob-
serving the content of the bottles. Appropriate delivery
of the IP cannot be verified by laboratory tests during
the intervention.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Even though the study products are not considered to
be medicinal drugs, and studies have so far not revealed
any serious adverse effects, study participants will be in-
sured by the Strategis Insurance in Tanzania (https://
www.strategis.co.tz/) for serious adverse events, includ-
ing hospitalization, disability, and death.
All study participants, when they fall sick during the
study period, will be treated according to the existing
standard of care at HLH. In addition, the study will pro-
vide C-reactive protein analysis, blood culture bottles,
and antimicrobial susceptibility testing of bacteria recov-
ered from blood culture for all children under one year
of age suspected of having sepsis. Malaria rapid test will
be performed if clinically indicated (Care Start, USA).
Laboratory results will be given to the attending phys-
ician to assist the patient management. During recruit-
ment, parents will have to agree for the child not to
participate in another study during the study period.
Provision for post-trial care {30}
As there is no anticipated harm for trial participation,
we have not planned for compensation or post-trial care.
Outcomes {12}
Primary outcome
Prevalence (%) of the composite outcome death and/or
hospitalizations at 6 months of age.
Secondary outcomes
 Rates (%) of ESBL-E colonization at 6 weeks and 6
months of age.
 Rates (%) of hospitalizations up to 6 months of age.
 Rates (%) of confirmed sepsis (blood culture-
confirmed) episodes up to 6 months of age.
 Growth monitored by length and weight up to 6
months of age.
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 Stool microbiota composition including resistome
analysis (metagenome sequencing) at 6 weeks and 6
months of age.
 Stool metabolome composition at 6 weeks and 6
months of age.
 Stool inflammatory markers at 6 months of age
 Genetic characteristics of ESBL-E from colonization




The infant mortality rate in Tanzania was in 2018 re-
ported at 3.8% [26]. We do not have exact data for the
Mbulu district, but we assume a similar rate of approxi-
mately 4%. Serious infections leading to hospitalization
are probably equally common, but hospitalization rates
may depend on available access. In the Panigrahi study
[15], the synbiotic product was given for only 7 days,
and it reduced the composite outcome of death and/or
infection from 9.0% to 5.4% during the first 2 months of
life. In our study, the intervention will continue for
around 4 weeks and follow-up will continue until 6
months of life. We consider a similar reduction in the
composite outcome of death and infections leading to
hospitalizations from 9.0% to 5.4%, as in the Panigrahi
study [15], to be clinically relevant. To find this differ-
ence with a study power of 85% at 5% significance level,
we will need a sample size of minimum of 924 cases in
each arm, thus 1848 infants. In order to allow for drop-
out, we aim to include 2000 infants. We believe it is real-
istic to include this number of infants within a 12-month
recruitment period. With this number of infants, we will
Fig. 1 Trial flow chart. Abbreviations: ESBL-E extended-spectrum beta-lactamase Enterobacteriaceae; MDR multidrug resistant
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also have sufficient power to detect a minimum of 30% re-
duction in ESBL-E colonization rate (from around 50% to
35%) at 6 months of age.
Recruitment {15}
Pregnant women in their last trimester, visited at
home or attending their last visit before delivery at
HLH, will receive oral and written information about
the study and asked for consent to let their future
child participate in the study. A study research assist-
ant speaking the native language will inform the
woman about all aspects of the study, including the
importance of performing such a study, and all proce-
dures that will take place during the study period. A
thorough explanation will also be given on how the
IP/placebo will be administered orally once daily with
five drops until the bottle is empty (4 weeks). Finally,
the importance of completing the dosage of the IP/
placebo for the 4-week intervention period will also
be explained to the woman. Information will be given
orally and by information included in a written in-
formed consent form (ICF).
If the woman, after this information, agrees for her
child to participate in the ProRIDE Trial, she will be
asked to give written consent to screen and enroll the
newborn baby in the study. The woman will receive a
special information card developed for the ProRIDE
Trial, after delivery and inclusion. During and after de-
livery, the attending doctor/midwives will identify
mothers who have consented to participate and inform
the research assistant, who will help coordinate the
study. After delivery, the newborn baby will be screened
for eligibility into the study, and if the baby fulfills the
inclusion criteria of the study, the baby will be enrolled
and allocated to the randomized product (active probio-
tics or placebo), which will be initiated on days 0–1 for
hospital deliveries or days 0–3 for home deliveries. The
mother will again be explained and demonstrated how
to administer the study product.
Assignment of interventions: allocation
Sequence generation {16a}
Prior to the start of the study, an independent researcher/
statistician at the University of Bergen will be in charge of
creating a computer-generated randomization list strati-
fied by site of delivery (home/hospital) with the study
identification number of patients, from 1 to 2000, and al-
located investigational product or placebo. We have not
planned for any restrictions to reduce the predictability of
the randomization list.
Concealment mechanism {16b}
Upon screening, the newborn infants will consecutively
be allocated (randomized) to the next study
identification number and given the corresponding in-
vestigational product/placebo, from the central storage
facility at HLH. The IP and placebo are identical in taste
and color and produced in identical bottles. A local
pharmacist, who is not part of the study, will be pro-
vided with the randomization list and will also label the
identical bottles, numbered from 1 to 2000.
Implementation {16c}
A staff member at the University of Bergen who will not
be involved in the trial will generate the allocation se-
quence using a computer software program. Research
assistants at HLH, who will not have access to the
randomization list, will be in charge of screening,
recruiting, and assigning interventions to participants.
Assignment of interventions: blinding
Who will be blinded {17a}
Both care providers (study participants are infants) and
investigators will be blinded for the assignment of the
intervention.
Procedure for unblinding if needed {17b}
A local pharmacist not involved in the study will have
access to the assignment list. Therefore, the study
principal investigator may request unblinding for
treatment assignment if needed for medical care of a
patient in an emergency situation. However, this is a
very unlikely situation given the well-known safety of
probiotics in infants, and the lack of known inter-
action with other important drugs used for any other
required therapy.
Study participants will be discontinued from partici-
pation in the study if (i) any clinical AE during the 4-
week intervention, laboratory abnormality, or other
medical condition or situation occurs such that con-
tinued participation is not in the best interest of the
participants, (ii) participants wish voluntary with-
drawal, (iii) participants are free to withdraw from
participating in the study at any time upon request
and/or [4] in any case participants will be given ap-
propriate care under medical supervision until the
symptoms of any AE resolve or the participant’s con-
dition becomes stable.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data collection
The information will be recorded on electronic CRFs
(eCRFs) using REDCap® (Research Electronic Data Cap-
ture). For enrolled infants, four different case reports
forms (CRFs) will be used to collect clinical and demo-
graphic information—three for the study visits and one
for AE/unscheduled visits due to hospitalization/
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outpatient clinic attendance for participants who fall sick
during the study period. The initial data at enrolment
will also be filled with the mother’s demographic and
clinical information (Table 1).
All staff members involved in data collection will re-
ceive training in utilizing the REDCap tool, as well as
training in Good Clinical Practice (GCP) guidelines.
Quality assessment of the data will be done by the in-
ternal clinical staff and consent forms and eCRFs will be
checked by external monitors.
Laboratory methods
Fecal samples and rectal swabs collected at 6 weeks and
6 months will be transported to Norway for the follow-
ing analyses (Table 1):
 Rectal swab samples (n = 4000) will be screened for
ESBL-E using selective ESBL-screening agar (Chro-
mID ESBL and ChromID Carba, BioMerieux). All
samples will be plated on non-selective plates for
growth control. ESBL-E isolated will be identified
using MALDI-TOF and subsequently frozen for gen-
etic analysis (whole genome sequencing and plasmid
analysis).
 Fecal samples (n = 4000) will be subjected to gut
microbiota and resistome analysis using a
metagenomics approach. This will be done on DNA
extracted from the fecal samples which have been
collected and stored using a purpose-designed sam-
pling kit (OMNIgen GUT kit, DNA Genotek,
Ottawa, Canada). These kits have been evaluated
using fresh stool samples compared to samples
stored in an OMNIgen GUT sampling tube. There
was no change in gut microbiota profile after the in-
cubation at 50 °C for 3 days consecutively and fol-
lowing six freeze-thaw cycles (information from the
manufacturer).
 Fecal samples (a subset of n = 500 samples) will be
subjected to gut metabolome studies. We will use
purpose-designed commercially available sampling
kits (OMNIgen GUT kit, DNA Genotek, Ottawa,
Canada) with proven stability of metabolites under
storage at ambient temperatures for up to 14 days.
Plans to promote participant retention and complete
follow-up {18b}
Firstly, all pregnant women will receive sufficient infor-
mation on what is expected from them if they allow for
their newborn to be recruited and the importance of
follow-up. During the study, we have scheduled three
follow-up visits where assigned research assistants will
visit households of participants; thus, participants will
not be burdened with the additional inconvenience of
traveling to the hospital and potentially falling out of the
study. Furthermore, all enrolled newborns will receive
insurance that will compensate for expenses related to
hospitalization/hospital visits during the trial period.
Mothers/caretakers will be encouraged to contact study
investigators in case they have any questions or concerns
regarding the study procedure.
Data management {19}
Data will be managed by using REDCap® tools hosted by
the University of Bergen [30]. REDCap is a web-based
software solution that permits secure storage, analysis,
and sharing of data by providing functions such as (i)
user authentication and role-based security, (ii) intuitive
electronic CRFs, (iii) real-time data validation and integ-
rity checks, (iv) trails for tracking data manipulation and
export procedures, and (v) export procedures for seam-
less data downloads to common statistical packages.
Tablet computers with REDCap software will be pro-
vided to research assistants and investigators. Passwords
will be created for each research assistant and investiga-
tor to get access to the study file in REDCap. Research
assistants will have access only to fill in the respective
CRFs of the study participants they recruit at each visit,
and they will have no access to change any information
entered in REDCap. Only study investigators will have
access to change information filled in REDCap when the
need arises. All data with identifiers will be stored on
firewall-protected secure servers, separately from clinical
and microbiological data.
For enrolled infants, four different CRFs will be used
for the study, three for the study visits and one for ad-
verse events/unscheduled visits due to hospitalization/
outpatient attendance for participants who fall sick dur-
ing the study period. Infant deaths, hospitalizations, and
sepsis episodes will also be recorded.
Confidentiality {27}
Data with identifying variables will be stored on firewall-
protected secure servers, separately from non-identifiable
information such as clinical and microbiological data.
Consent forms from mothers/caretakers will be safely
stored separately from the collected data in a locked
cabinet.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic analysis in this trial/
future use {33}
Standard operating procedures (SOP) which have been
developed for the study will be used for specimen collec-
tion and processing. One fecal sample and one rectal
swab sample will be collected at 6 weeks and 6 months
visits, respectively. The fecal samples will be obtained
using commercially available sampling kits (OMNIgen
GUT kit, DNA Genotek, Ottawa, Canada) allowing
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storage of samples at ambient temperatures for up to 7–
14 days before DNA extraction or freezing. These sam-
ples will be transported to HLH latest within 3 days after
sampling and at HLH stored in − 80 °C freezers. The rec-
tal swab samples will be taken by a research assistant
using eSwab (Copan Diagnostics, CA, USA), transported
to the laboratory at HLH the same day, and frozen at −
80 °C freezers until analysis.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Clinical data
In univariate analysis, comparison of proportions will be
done using Pearson’s chi-squared test and comparison of
means will be done using t test or non-parametric tests
as appropriate. Logistic regression will be used for multi-
variate analysis when assessing the relative importance
of risk factors for the carriage of ESBL-E and other
multi-resistant bacteria. The analysis will be performed
in Stata 13 (Stata Corporation, College Station, Texas).
Stool microbiota, stool metabolome, and stool
inflammatory markers
Stool microbiota
A Poisson generalized linear model will be used to cal-
culate trends in the relative abundance of genera and
antibiotic resistance genes in the stool microbiota. Cor-
rections based on multiple comparisons will be per-
formed by the Benjamini-Hochberg false discovery rate
(FDR). An FDR Q value ≤.10 will be considered signifi-
cant for any analyses with multiple comparisons. A
standard P value ≤.05 will be considered significant for
all other analyses. Alpha diversity of the gut microbiota
will be assessed by calculating the Shannon Diversity
Index (MEGAN, v5.10.6). Multiple beta diversity metrics
of samples will be performed by using non-metrical
multidimensional scaling (NMDS), based on a matrix of
Bray-Curtis distances and calculated by using the vegan
R package. Differences between groups will be tested by
using permutational multivariate analysis on beta diver-
sity matrices.
Stool metabolites will be identified by using mass
spectral databases (e.g., MzCloud, Metlin) and stan-
dards purchased for this project. For statistical and
pathway analyses, we will use web-based tool Meta-
boAnalyst. All MS data will be submitted to and
stored at the European Bioinformatics Institute re-
pository MetaboLights.
Stool inflammatory markers will be analyzed with con-
ventional statistical tools for interval data using paramet-
ric or non-parametric tests, as appropriate.
Composition of the data monitoring committee, its role,
and reporting structure {21a}
A data safety monitoring body (DSMB) has been
appointed, which will periodically conduct scheduled,
and in the case of AE, unscheduled reviews. The DSMB
consists of our experts from both Norway and Tanzania.
The DSMB will evaluate the accumulated study data
with the main goal of ensuring that the rights and well-
being of participants are protected. Site monitoring will
also ensure that the conduct of the RCT adheres with
the study protocol, good clinical practice (GCP), good la-
boratory practice (GCLP), and applicable regulatory re-
quirements. In addition to ensuring the well-being of
study participants, the DSMB will verify that the re-
ported clinical and laboratory data are accurate,
complete, and verifiable from the source data, ultimately
providing recommendations to the ProRIDE study con-
sortium concerning the continuation, modification, or
termination of the trial, if necessary. The DSMB will al-
ways maintain confidentiality during all phases of DSMB
review, including internal discussions and activities, and
contents of reports provided by it. Usually, only voting
members of the DSMB will have access to interim ana-
lyses of outcome data by treatment group. Exceptions
may be made when the DSMB deems it appropriate.
The DSMB is independent from the sponsor and has no
competing interests.
Interim analyses {21b}
We plan for interim analyses after the recruitment of
500 and 1000 infants. The major outcomes of interest;
mortality, hospitalizations, and blood culture-confirmed
sepsis will be summarized and presented to the DSMB.
Only the study statistician and the PIs of the study, in
addition to the DSMB, will have access to these results.
If mortality between groups (probiotic vs placebo) is sig-
nificantly different at assessment at these time points of
the study, the study will be stopped. This decision will
be taken by the PIs of the study, in consultation with co-
investigators and the DSMB. Other triggers that would
call for an unscheduled DSMB review are if infant mor-
tality or morbidity rates clearly exceed expected rates in
Tanzania.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
Depending on the final results, it may be relevant to
conduct subgroup analyses. Studies have shown that
even short hospitalizations increase the risk of ESBL-E
gut colonization [31, 32], and thus, it may be relevant to
conduct subgroup analyses where participants will be
stratified according to the place of birth (hospital/home).
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Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
We will handle patient data according to the
intention-to-treat principle. Patients will be com-
pared—in terms of their final results—within the
groups to which they were initially randomized, inde-
pendently of receiving the allocated treatment, having
dropped out of the study, or having violated the ini-
tial protocol (for whatever reason). This is a RCT and
missing data will most likely occur at random be-
tween the two groups. We aim specifically to record
a simple core set of clinical primary outcomes (mor-
tality and morbidity assessed primarily as
hospitalization) in order to minimize the occurrence
of missing values. Missing data will be discarded from
further analysis, and thus, participants with missing
data on the primary outcome will be omitted from
the main analysis.
Plans to give access to the full protocol, participant level-
data, and statistical code {31c}
Data sharing statement
The raw data from this study will be made available by
the authors, without undue reservation, to any qualified
researcher no later than 3 years after the publication of
the main study. Moreover, we will deliver a completely
de-identified data set to an appropriate data archive for
sharing purposes. Pathogen genomes that are sequenced
will be made available for other researchers in
GenBank®.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
The consortium consists of partners that have compe-
tence in diverse and complementary scientific fields, in-
cluding infectious disease, pediatrics, clinical
microbiology, and bioinformatics. NL, who will lead the
consortium, BB, and SJM have experience in clinical
studies in low-income settings with a particular focus on
antimicrobial resistance. All of these partners (NL, BB,
SJM) have also conducted research regarding ESBL-E re-
sistance in children. CK is an experienced pediatrician/
neonatologist with experience from clinical work in
Tanzania, as well as research on infections and the use
of antibiotics in neonates. He has recently completed a
study using metagenome analyses of gut microbiota and
resistome in stool samples of preterm infants. Clinical
microbiologists IL and JM have experience in research
on ESBL-E and will be in charge of overseeing laboratory
procedures in Tanzania and Norway. JG at the Pediatric
Department is the HLH partner and local clinical princi-
pal investigator.
Adverse event reporting and harms {22}
The DSMB are in charge of conducting unscheduled re-
views in the case of adverse events, ultimately providing
recommendations to the ProRIDE study consortium
concerning the continuation, modification, or termin-
ation of the trial.
Frequency and plans for auditing trial conduct {23}
Site monitoring will be conducted to ensure that the
rights and well-being of study participants are protected.
In addition, monitoring will verify that the reported clin-
ical and laboratory data are accurate, complete, and veri-
fiable from source data. Site monitoring will also ensure
that the conduct of the clinical trial is in adherence with
the study protocol, good clinical practice (GCP), and
good laboratory practice (GCLP) and applicable regula-
tory requirements (Tables 2 and 3).
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Any recommendations from the DSMB will firstly be
communicated to the consortium. If changes in protocol
are to be made, the following relevant parties will be
informed:
 National Institute of Medical Research in Tanzania
(NIMR), Tanzania
 Tanzania Medicines and Medical Devices Authority
(TMDA), Tanzania
 The Regional Committee for Medical and Health
Research Ethics Western Norway, Norway
Dissemination plans {31a}
The final report will be prepared by the Principal Inves-
tigator and Co-investigators. Study participants will be
informed of the study results. The health care workers at
HLH where the study will be conducted will be informed
of the results obtained. The results will also be made
available to the Ministry of Health and Social Welfare.
Study findings will also be published in international
peer-reviewed journals, preferably in journals which are
available free of charge, so that the information can be
accessible to health professionals in the settings where
the study will be conducted. In addition, results will be
given to participating hospitals and to governmental
bodies responsible for guidelines for infant treatment
and prophylaxis.
Discussion
Despite promising results regarding the use of probiotics
to reduce the carriage of MDR bacteria, no RCT has in-
vestigated whether probiotics may reduce ESBL-E gut
colonization in infants [16, 25]. Therefore, the ProRIDE
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Trials aim to evaluate whether the use of probiotics can
reduce infection-related morbidity and mortality by pre-
venting ESBL-E colonization and/or infections among
infants in Haydom, Tanzania. The RCT is a large-size
study with a rigorous design. By using a large sample
size and applying bias-reducing techniques, such as
randomization and blinding, we can provide robust evi-
dence that is necessary to evaluate whether probiotics
can significantly reduce morbidity and mortality related
to ESBL-E colonization among infants in Haydom,
Tanzania.
Methodological considerations
Our aim is to recruit 2000 infants in Haydom and the
surrounding area, more specifically newborns who are
delivered at HLH or at home. Recruiting newborns de-
livered at HLH is expected to be feasible due to experi-
enced research infrastructure and available research
nurses at HLH. We expect more challenges in
identifying and recruiting women who plan to deliver at
home. Own fieldworkers will be in charge of conducting
field visits to identify potential mothers in their last tri-
mester, screening newborns, and enrolment and follow-
up of eligible newborns. Although this may be challen-
ging, HLH has long-standing experience with running
mobile clinics and conducting community research [33].
Furthermore, the recruitment of newborns delivered
outside the hospital is of importance due to two reasons.
Firstly, women who give birth at home may be signifi-
cantly different from women delivering at the hospital in
terms of socioeconomic status [34, 35]. Utilization of
health care services and delivery at the hospital is costly
due to traveling and consultation fees, and women who
cannot afford these expenses may choose to deliver at
home. Given that ESBL-E gut colonization is associated
with lower socioeconomic status [36, 37], it is important
that infants of such families are recruited in order to ob-
tain a representable sample of the population of interest.
Table 2 Monitoring plan
1st quarter 2nd quarter 4th quarter 8th quarter
Enrolment visit x
Follow-up visit x x
Close up x
Table 1 Trial schedule procedures
Study period
Enrolment Allocation Post-allocation
Timepoint Screening Baseline 7 days* 6 weeks 6months
Enrolment
Informed consent mother/caretaker x






Rates of confirmed sepsis episodes x x
Rates of hospitalization x x
Growth by height and weight x x
Stool microbiota composition and resistome x x
Stool metabolome composition x x
Stool inflammatory markers x
Genetic characteristics of ESBL-E and other MDR isolates x x
Prevalence ESBL-E carriage x x
Abbreviations: ESBL-E extended-spectrum beta-lactamase Enterobacteriaceae, MDR multidrug resistant
*Observe for adherence and discuss issues with care takers
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Secondly, because hospitalization is associated with
ESBL-E colonization, exclusively recruiting newborns
delivered at the hospital may yield a sample where the
baseline colonization rate does not truly reflect the base-
line in the population of interest.
Probiotics/placebo drops will be administered at home
by mothers, and thus, we cannot directly observe if the
infants are receiving the drops appropriately. However,
during the recruitment of mothers in their last trimester,
enrolment of newborns, and the first follow-up visit,
mothers will be explained how the drops are to be ad-
ministered and the importance of completing the course
appropriately. Moreover, adherence will also be evalu-
ated during the first and second follow-up visits by ob-
serving the content of the bottles.
Ethical equipoise and risk
There is a genuine uncertainty about the effect of the
intervention on morbidity and mortality compared to
what is being offered to the control group—placebo. The
Panigrahi trial was performed in a different continent
with a probiotic product combined with a prebiotic [15].
The effects observed in India were strikingly positive,
but need to be confirmed in other large trials before this
can be introduced as standard care for newborn infants
in low-income countries.
There is currently no recommended therapy for pre-
venting ESBL-E gut colonization and conducting this
trial does not breach the ethical equipoise. Furthermore,
included infants—both in the intervention arm and
control arm—who may be sick and need hospitalization
for any illnesses will receive standard care treatment at
HLH, including study-funded optimal assessment of a
potential infection with blood culture and CRP analyses
(ancillary care).
Infants included in this trial will not undergo any pain-
ful procedures, in particular, no extra blood samples will
be obtained. The IP is not likely to cause severe side ef-
fects or harm [19], given the well-known safety of pro-
biotics in infants, and the lack of known interaction with
other important drugs used for any other required ther-
apy. Therefore, it is considered that the risk associated
with trial participation is minimal. Even though the
study products are not considered to be medicinal drugs,
and studies have so far not revealed any serious adverse
effects, study participants will also be insured, if unfore-
seen side effects of the probiotics develop.
Local support
HLH has a strong and well-established research infra-
structure. It has recently been involved in larger studies
such as MAL-ED [33] and Helping Babies Breathe [38],
and over the past 10 years, the hospital has been in-
volved in community research, which has built trust be-
tween the hospital and the community around [39]. To
explore the attitude and acceptability towards the inter-
vention, we will also, before study-start, perform focus
group discussions with women caring for infants. Advice
from the mothers in the ProRIDE Trial will be
Table 3 Key activities of the clinical monitor
Site visits When Key activities
Monitoring visit during enrolment One visit, 4 weeks since the start of enrolment. - Inspection of all ICH GCP certificates in place
- Verification of informed consent forms
- Eligibility check
- eCRF completion
- Equipment, consumables, study material
- Review laboratory sample management
Monitoring visit follow-up—first One visit 6 months since the start of enrolment. - Specimen collection procedure
- Eligibility check
- eCRF completion
- Eligibility of source documents
- Source data verification
- Review AE/SAE reporting
Monitoring visit follow-up—second One visit 12 months since the start of enrolment. - Specimen collection procedure
- Eligibility check
- eCRF completion
- Eligibility of source documents
- Source data verification
- Review AE/SAE reporting
Close-up visit monitoring One visit 18 months since the start of enrolment
(end of study)
- Last query resolution
- Storage and archiving of documentation
- Review, update, and finalization of IF
Abbreviations: AE/SAE adverse events/serious adverse events, eCRF electronic case report forms, ICH GCP International Conference on Harmonization Good Clinical
Practice, IF investigator file
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particularly valuable if the trial results are to be imple-
mented in routine infant care.
Potential impact
The hypothesis in the ProRIDE Trial is that probiotics
will significantly reduce hospitalization and death (as a
composite outcome) up to 6 months of age. Moreover,
we hypothesize that the intervention may be associated
with a reduction in ESBL-E-carriage and infections.
Thus, the ProRIDE trial will benefit participants, care-
takers, and health personnel, with the aim of ensuring
improved clinical health of participants and obtaining an
in-depth understanding of the effects of probiotics in
children. It is a simple intervention that is realistic to
implement even outside a controlled, research environ-
ment. Because probiotics does not need to be adminis-
tered in the hospital or by a health professional, and is
to our knowledge not associated with any serious ad-
verse side effects, it is likely that it can be administered
at home by caretakers.
If the hypothesis of the ProRIDE Trial is confirmed,
the study results will also be helpful for government offi-
cials responsible for national guidelines, as it will sup-
port the implementation of probiotic use in routine
clinical care to reduce morbidity and improve survival of
infants in low-income settings. If the study confirms
probiotics as an efficient tool to reduce carriage of
ESBL-E, this may also have implications far beyond the
study setting, including in Norway, as ESBL-E carriage
has rapidly developed into a global challenge. Lastly,
AMR is posing a major threat to human health globally,
and a reduction in the prevalence of AMR would subse-
quently lead to reduced consumption of broad-spectrum
antibiotics and thereby reduce drivers of resistance.
Trial status
At the time of this submission, the trial has been ap-
proved by REK, NIMR, and TMDA. Recruitment of par-
ticipants was expected to start in November 2020 and be
completed in November 2021. However, the current
COVID-19 pandemic has already substantially delayed
the study start, and there is also an uncertainty around
further development of the pandemic and its impact on
clinical research in Tanzania, and many other countries
in the world. We now are planning to start the study in
the second half of 2021.
Protocol version: March 2021, version 1.1.
Abbreviations
AE/SAE: Adverse events/serious adverse events; AMR: Antimicrobial
resistance; BSI: Bloodstream infection; CRF: Case report form; DSMB: Data
safety monitoring body; DTA: Data transfer agreement; ESBL: Extended-
spectrum beta-lactamase Enterobacteriaceae; ESBL-E: Extended-spectrum
beta-lactamase-producing; eCRF: Electronic case report forms; FDR: False
discovery rate; GCP: Good Clinical Practice; GCLP: Good Laboratory Practice;
GMP: Good Manufacturing Processes; GPP: Good Production Practices;
HLH: Haydom Lutheran Hospital; ICF: Informed consent form;
IP: Investigational product; IRB: Ethical approval; MDR: Multi-drug-resistant;
MTA: Material transfer agreement; NIMR: National Institute of Medical
Research in Tanzania; NMDS: Non-metrical multidimensional scaling;
RCT: Randomized controlled trial; REK: Regional Committee for Medical and
Health Research Ethics of Western Norway; WHO: World Health Organization
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13063-021-05251-3.
Additional file 1. 7221 Probiotika til nyfødte for å redusere kolonisering
og sykdom med resistente bakterier.
Additional file 2. Letter of ethical review REC West.
Additional file 3. Re: ethical clearance certificate for conducting
medical research in Tanzania.
Additional file 4. Tildeling av Helse Vests forskingsmidlar 2019 - Åpen
prosjektstøtte.
Additional file 5. Letter of financial support.
Acknowledgements
We thank the hospital administration at HLH for being positive about this
study. Relevant parties will be acknowledged when study results are
published, including participants/parents, staff at the pediatric ward and field
workers at HLH, and laboratory technicians.
Authors’ contributions {31b}
CK and NL conceptualized the study. NL, CK, SJM, IL, BB, and JG all made
substantial contributions to the study protocol. KK and CK wrote the first
draft of this manuscript, and all authors critically revised the manuscript. The
authors read and approved the final version of this manuscript.
Funding {4}
This trial has received funding from the Western Norway Regional Health
Authority. The funding body had no role in the design of the study and will
not have any role during the collection, analysis, and interpretation of data
and in writing the manuscript.
Availability of data and materials {29}
The final trial dataset from this study will be made available by the authors
to any qualified researcher no later than 3 years after the publication of the
main study. Moreover, we will deliver a de-identified dataset to an appropri-
ate data archive for sharing purposes.
Declarations
Ethics approval and consent to participate {24}
This study will be conducted in accordance with the latest South Africa
revision of the Declaration of Helsinki, good clinical practice, and local and
international regulatory requirements. Ethical approval of the ProRIDE Trial
has been obtained from the Regional Committee for Medical and Health
Research Ethics Western Norway in September 2019 (REK Vest 2019/1025)
(see “Additional file 1”) and from the National Institute of Medical Research
in Tanzania (NIMR) in April 2020 (see “Additional file 2”). The formal
application to conduct the RCT in Tanzania has in June 2020 been
submitted to the regulatory authority; Tanzania Medicines and Medical
Devices Authority (TMDA). A response to queries raised by TMDA was
submitted in December 2020. Approval has been obtained from TMDA, but
technical issues have caused delays in the release of the certificate. Parent/
caretaker will receive oral and written information about the trial and must
give a written informed consent before their involvement in the trial. All
information is translated in Kiswahili and trained investigators participating in
the recruitment process speak the local languages. Participants are free to
withdraw from the trial at any time.
Kuwelker et al. Trials          (2021) 22:312 Page 12 of 14
Consent for publication {32}
No individual or sensitive data relating to an individual person will be
published. Thus, we do not need an informed consent from a person or a
parent/legal guardian for the final publication.
Competing interests {28}
The authors declare that they have no competing interests.
Author details
1Norwegian National Advisory Unit on Tropical Infectious Diseases,
Haukeland University Hospital, Haukelandsbakken, 5009 Bergen, Norway.
2Department of Clinical Science, University of Bergen, Laboratory Building,
Haukeland University Hospital, Jonas Lies veg 87, 5021 Bergen, Norway.
3Department of Medical Microbiology, Stavanger University Hospital, Gerd
Ragna Bloch Thorsens gate, 4011 Stavanger, Norway. 4Department of
Paediatrics, Haydom Lutheran Hospital, Mbulu, Manyara, Tanzania.
5Department of Microbiology and Immunology, Muhimbili University of
Health and Allied Sciences, MUHAS, P.O. Box 65005, Dar es Salaam, Tanzania.
6Department of Paediatrics and Adolescence Medicine, University Hospital of
North Norway, Tromsø, Norway. 7Paediatric Research Group, Faculty of
Health Sciences, University of Tromsø-Arctic University of Norway, Tromsø,
Norway.
Received: 1 September 2020 Accepted: 7 April 2021
References
1. Kipp AM, Blevins M, Haley CA, Mwinga K, Habimana P, Shepherd BE, et al.
Factors associated with declining under-five mortality rates from 2000 to
2013: an ecological analysis of 46 African countries. BMJ Open. 2016;6(1):
e007675.
2. Collaborators GBDM. Global, regional, and national under-5 mortality, adult
mortality, age-specific mortality, and life expectancy, 1970–2016: a
systematic analysis for the Global Burden of Disease Study 2016. Lancet.
2017;390(10100):1084–150.
3. Organization WH. Global priority list of antibiotic-resistant bacteria to guide
research, discovery, and development of new antibiotics 2017 [updated 27
February 2017. Available from: https://www.who.int/medicines/publications/
global-priority-list-antibiotic-resistant-bacteria/en/.
4. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, et al.
High rate of fatal cases of pediatric septicemia caused by gram-negative
bacteria with extended-spectrum beta-lactamases in Dar es Salaam,
Tanzania. J Clin Microbiol. 2005;43(2):745–9.
5. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, et al.
Antimicrobial resistance predicts death in Tanzanian children with
bloodstream infections: a prospective cohort study. BMC Infect Dis. 2007;7:
43.
6. Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E, et al.
Prevalence, risk factors, and impact on clinical outcome of extended-
spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year
study. Int J Infect Dis. 2015;39:1–6.
7. Bert F, Larroque B, Paugam-Burtz C, Dondero F, Durand F, Marcon E, et al.
Pretransplant fecal carriage of extended-spectrum beta-lactamase-
producing Enterobacteriaceae and infection after liver transplant, France.
Emerg Infect Dis. 2012;18(6):908–16.
8. Marando R, Seni J, Mirambo MM, Falgenhauer L, Moremi N, Mushi MF, et al.
Predictors of the extended-spectrum-beta lactamases producing
Enterobacteriaceae neonatal sepsis at a tertiary hospital, Tanzania. Int J Med
Microbiol. 2018;308(7):803–11.
9. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal
carriage of extended-spectrum beta-lactamases in the community: toward
the globalization of CTX-M. Clin Microbiol Rev. 2013;26(4):744–58.
10. Tellevik MG, Blomberg B, Kommedal O, Maselle SY, Langeland N, Moyo SJ.
High prevalence of faecal carriage of ESBL-producing Enterobacteriaceae
among children in Dar es Salaam, Tanzania. PLoS One. 2016;11(12):
e0168024.
11. Lenfestey MW, Neu J. Probiotics in newborns and children. Pediatr Clin N
Am. 2017;64(6):1271–89.
12. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis
in preterm infants. Evid Based Child Health. 2014;9(3):584–671.
13. Rao SC, Athalye-Jape GK, Deshpande GC, Simmer KN, Patole SK. Probiotic
supplementation and late-onset sepsis in preterm infants: a meta-analysis.
Pediatrics. 2016;137(3):e20153684.
14. Deshpande G, Jape G, Rao S, Patole S. Benefits of probiotics in preterm
neonates in low-income and medium-income countries: a systematic
review of randomised controlled trials. BMJ Open. 2017;7(12):e017638.
15. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A
randomized synbiotic trial to prevent sepsis among infants in rural India.
Nature. 2017;548(7668):407–12.
16. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-
resistant pathogens. Science. 2016;352(6285):535–8.
17. Ouwehand AC, Forssten S, Hibberd AA, Lyra A, Stahl B. Probiotic approach
to prevent antibiotic resistance. Ann Med. 2016;48(4):246–55.
18. Agamennone V, Krul CAM, Rijkers G, Kort R. A practical guide for probiotics
applied to the case of antibiotic-associated diarrhea in the Netherlands.
BMC Gastroenterol. 2018;18(1):103.
19. Perceval C, Szajewska H, Indrio F, Weizman Z, Vandenplas Y. Prophylactic
use of probiotics for gastrointestinal disorders in children. Lancet Child
Adolesc Health. 2019;3(9):655–62.
20. Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum
subspecies infantis: champion colonizer of the infant gut. Pediatr Res. 2015;
77(1–2):229–35.
21. Taft DH, Liu J, Maldonado-Gomez MX, Akre S, Huda MN, Ahmad SM, et al.
Bifidobacterial dominance of the gut in early life and acquisition of
antimicrobial resistance. mSphere. 2018;3(5):e00441-18.
22. Parnanen K, Karkman A, Hultman J, Lyra C, Bengtsson-Palme J, Larsson DGJ,
et al. Maternal gut and breast milk microbiota affect infant gut antibiotic
resistome and mobile genetic elements. Nat Commun. 2018;9(1):3891.
23. Moubareck C, Lecso M, Pinloche E, Butel MJ, Doucet-Populaire F. Inhibitory
impact of bifidobacteria on the transfer of beta-lactam resistance among
Enterobacteriaceae in the gnotobiotic mouse digestive tract. Appl Environ
Microbiol. 2007;73(3):855–60.
24. Casaburi G, Duar RM, Vance DP, Mitchell R, Contreras L, Frese SA, et al. Early-
life gut microbiome modulation reduces the abundance of antibiotic-
resistant bacteria. Antimicrob Resist Infect Control. 2019;8:131.
25. Esaiassen E, Hjerde E, Cavanagh JP, Pedersen T, Andresen JH, Rettedal SI,
et al. Effects of probiotic supplementation on the gut microbiota and
antibiotic resistome development in preterm infants. Front Pediatr. 2018;6:
347.
26. United Nations Inter-agency Group for child mortality estimation - Tanzania
[Internet]. 2018. Available from: https://childmortality.org/data/United%2
0Republic%20of%20Tanzania.
27. Robertson C, Savva GM, Clapuci R, Jones J, Maimouni H, Brown E, et al.
Incidence of necrotising enterocolitis before and after introducing routine
prophylactic Lactobacillus and Bifidobacterium probiotics. Arch Dis Child
Fetal Neonatal Ed. 2020;105(4):380-6.
28. Klingenberg C. Metodebok i nyfødtmedisin. Tromsø, Norway: The University
Hospital of North Norway; 2019.
29. Pernica JM, Steenhoff AP, Mokomane M, Moorad B, Lechiile K, Smieja M,
et al. Rapid enteric testing to permit targeted antimicrobial therapy, with
and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal
disease in Botswana: a pilot, randomized, factorial, controlled trial. PLoS
One. 2017;12(10):e0185177.
30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)--a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81.
31. Schaumburg F, Alabi A, Kokou C, Grobusch MP, Kock R, Kaba H, et al. High
burden of extended-spectrum beta-lactamase-producing
Enterobacteriaceae in Gabon. J Antimicrob Chemother. 2013;68(9):2140–3.
32. Moremi N, Claus H, Rutta L, Frosch M, Vogel U, Mshana SE. High carriage
rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae
among patients admitted for surgery in Tanzanian hospitals with a low rate
of endogenous surgical site infections. J Hosp Infect. 2018;100(1):47–53.
33. Investigators M-EN. The MAL-ED study: a multinational and multidisciplinary
approach to understand the relationship between enteric pathogens,
malnutrition, gut physiology, physical growth, cognitive development, and
immune responses in infants and children up to 2 years of age in resource-
poor environments. Clin Infect Dis. 2014;59(Suppl 4):S193–206.
34. Moyer CA, Mustafa A. Drivers and deterrents of facility delivery in sub-
Saharan Africa: a systematic review. Reprod Health. 2013;10:40.
Kuwelker et al. Trials          (2021) 22:312 Page 13 of 14
35. Yaya S, Bishwajit G, Gunawardena N. Socioeconomic factors associated with
choice of delivery place among mothers: a population-based cross-sectional
study in Guinea-Bissau. BMJ Glob Health. 2019;4(2):e001341.
36. Founou RC, Founou LL, Essack SY. Extended spectrum beta-lactamase
mediated resistance in carriage and clinical gram-negative ESKAPE bacteria:
a comparative study between a district and tertiary hospital in South Africa.
Antimicrob Resist Infect Control. 2018;7:134.
37. Herindrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buisson Y,
Genel N, et al. Rectal carriage of extended-spectrum beta-lactamase-
producing gram-negative bacilli in community settings in Madagascar. PLoS
One. 2011;6(7):e22738.
38. Nelissen E, Ersdal H, Mduma E, Evjen-Olsen B, Twisk J, Broerse J, et al.
Clinical performance and patient outcome after simulation-based training in
prevention and management of postpartum haemorrhage: an educational
intervention study in a low-resource setting. BMC Pregnancy Childbirth.
2017;17(1):301.
39. Mduma ER, Gratz J, Patil C, Matson K, Dakay M, Liu S, et al. The etiology, risk
factors, and interactions of enteric infections and malnutrition and the
consequences for child health and development study (MAL-ED):
description of the Tanzanian site. Clin Infect Dis. 2014;59(Suppl 4):S325–30.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kuwelker et al. Trials          (2021) 22:312 Page 14 of 14
